Clinical trial
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine…
NCT00044031 · Cancer Advances Inc., Industry · Completed
Key facts
| NCT number | NCT00044031 |
|---|---|
| Title | Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma |
| Official title | Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following… |
| Lead sponsor | Cancer Advances Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | G17DT Immunogen |
| Enrollment | 394 |
| Start date | Feb 1, 2001 |
| Primary completion | Apr 1, 2004 |
| Completion | Oct 1, 2007 |
| First posted | Aug 20, 2002 |
| Last update posted | Apr 17, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: